Nalmefene (trade name: Selincro) has been approved in Germany since February 2013 for the treatment of alcohol dependency in people who show no physical withdrawal symptoms and do not require immediate detoxification. This drug is an option for people who want to lower their alcohol intake but have not been successful on their own within two weeks. Daily alcohol intake must be more than 60 g for men or 40 g for women, which is the equivalent of about three bottles of beer for men and two bottles for women.
Nalmefene is particularly suitable for men and women who want to stop drinking alcohol completely but are on a waiting list to start therapy.
Nalmefene influences the production of neurotransmitters in the brain, lowering the craving for alcohol.
Patients take one tablet of nalmefene on days when they feel the urge to drink alcohol. The daily dosage is 18 milligrams. People with an alcohol dependency are often aware of what time of day their urge for alcohol will start. The drug should be taken one or two hours beforehand.
The treatment is combined with psychosocial support such as counseling, behavioral therapy or psychotherapy.
If using medication to reduce alcohol intake is an option, the drug naltrexone has been standard therapy. Use of naltrexone should also be complemented by counseling, behavioral therapy or psychotherapy.
In late 2014 the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) assessed the advantages and disadvantages of nalmefene and psychosocial support compared with previous standard therapies for people with alcohol dependency.
However, the manufacturer did not provide any data suitable for answering this question, so it is not possible to judge whether nalmefene has any advantages or disadvantages.
This information summarizes the main results of a review produced by the Institute for Quality and Efficiency in Health Care (IQWiG, Germany). The review was commissioned by the German Federal Joint Committee (G-BA) as part of the "early benefit assessment of medications." On the basis of this review and the hearings received, G-BA passed a resolution on the added benefit of nalmefene (Selincro).
Institute for Quality and Efficiency in Health Care (IQWiG, Germany). Nalmefene - Benefit assessment according to §35a Social Code Book V. Dossier assessment A14-30. Cologne: IQWiG. December 1, 2014.
IQWiG health information is written with the aim of helping people understand the advantages and disadvantages of the main treatment options and health care services.
Because IQWiG is a German institute, some of the information provided here is specific to the German health care system. The suitability of any of the described options in an individual case can be determined by talking to a doctor. We do not offer individual consultations.
Our information is based on the results of good-quality studies. It is written by a team of health care professionals, scientists and editors, and reviewed by external experts. You can find a detailed description of how our health information is produced and updated in our methods.